Fennec Pharmaceuticals
FENC
28 hedge funds and large institutions have $64.1M invested in Fennec Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 3 closing their positions.
291% more call options, than puts
Call options by funds: $461K | Put options by funds: $118K
28% more capital invested
Capital invested by funds: $49.9M → $64.1M (+$14.1M)
0.35% more ownership
Funds ownership: 43.63% → 43.98% (+0.35%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 30 → 28 (-2)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Solas Capital Management
Darien,
Connecticut
|
+$1.4M |
| 2 |
DCM
DG Capital Management
New York
|
+$258K |
| 3 |
JP Morgan Chase
New York
|
+$82.1K |
| 4 |
Morgan Stanley
New York
|
+$46.2K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$16.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$1.13M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$65K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$33.7K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$32.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$29.4K |
FENC Hedge Fund Activity: Q1 2022 in Review
28 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q1 2022, worth a combined $64.1M — up 28% from $49.9M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of FENC and 1 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was Solas Capital Management, adding an estimated $1.4M. The largest seller was 683 Capital Management, cutting an estimated $1.13M.
- 28 institutional investors held Fennec Pharmaceuticals (FENC) as of Q1 2022, down from 30 in Q4 2021.
- Funds reported $64.1M of Fennec Pharmaceuticals stock for Q1 2022, up 28% quarter-over-quarter.
- 1 fund opened new Fennec Pharmaceuticals positions in Q1 2022 and 3 closed out, a net change of -2 holders.
- The largest Fennec Pharmaceuticals buyer in Q1 2022 was Solas Capital Management, an estimated $1.4M added.
- The largest Fennec Pharmaceuticals seller in Q1 2022 was 683 Capital Management, an estimated $1.13M sold.
Based on aggregated 13F filings for Q1 2022.